Advertisement

Topics

Cosmo Pharmaceuticals Announces Submission of Remimazolam NDA to FDA

00:04 EDT 9 Apr 2019 | Drugs.com

Dublin – April 9, 2019 – Cosmo Pharmaceuticals NV (SIX: COPN) today informed that the Remimazolam NDA has been submitted to FDA. Electronic acknowledgment of the submission shows April 5 as the official date of submission. Therefore...

Original Article: Cosmo Pharmaceuticals Announces Submission of Remimazolam NDA to FDA

NEXT ARTICLE

More From BioPortfolio on "Cosmo Pharmaceuticals Announces Submission of Remimazolam NDA to FDA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...